Jourdeness Group Ltd. (4190) AI Stock Analysis

Jourdeness Group Ltd.

(TWSE:4190)

Select Model

Rating:40Underperform

Price Target:TWD 21.00▼(-4.33% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is driven primarily by weak profitability, balance-sheet pressure, and a persistent technical downtrend. Improved cash generation and the modest dividend yield provide limited support, but the negative P/E and continued net losses keep the overall outlook weak.

Positive Factors

Resilient Gross MarginsSustained gross margins in the mid-60% range indicate that Jourdeness retains meaningful economics in its offerings. Although below earlier levels, this underlying margin base can support recovery if operating costs and other expenses are brought under better control over the next several quarters.

Negative Factors

Recurring Net LossesNet losses across three consecutive years show that the company’s gross-profit base is not translating into sustainable bottom-line earnings. Continued losses can weaken equity, constrain reinvestment, and make the business more dependent on operational improvement or external financing.

Jourdeness Group Ltd. (4190) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.33B
Dividend Yield: 2.28%
Average Volume (3M): 20.41K
Price to Earnings (P/E): -13.6
Beta (1Y): 0.40
Revenue Growth: -1.05%
EPS Growth: 34.07%
Country: TW
Employees: 6,108
Sector: General
Sector Strength: 55
Industry: Household & Personal Products

Jourdeness Group Ltd. Business Overview & Revenue Model

Company Description

Jourdeness Group Limited, together with its subsidiaries, manufactures and sells cosmetics in China, Taiwan, and internationally. The company also engages in the beauty and body spa business; and operation of a tourist factory, as well as offers cons...

Jourdeness Group Ltd. Financial Statement Overview

Summary

Financial performance is weak overall: the company remains unprofitable with negative operating profitability, elevated leverage, declining equity, and revenue below historical highs. Improved 2025 cash flow and modest debt reduction provide limited support. The score is constrained at the minimum range because the provided income statement score was below 37.

Income Statement

35Negative

Balance Sheet

42Neutral

Cash Flow

58Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.26B	2.31B	2.28B	2.98B	2.78B	2.82B
Gross Profit	1.32B	1.48B	1.40B	2.01B	1.89B	2.06B
EBITDA	417.11M	615.39M	535.32M	878.66M	802.49M	1.14B
Net Income	-83.95M	-94.26M	-291.95M	-258.00K	13.98M	292.16M
Balance Sheet
Total Assets	7.25B	6.79B	7.39B	7.86B	8.05B	8.44B
Cash, Cash Equivalents and Short-Term Investments	1.77B	1.16B	1.15B	1.33B	1.37B	2.44B
Total Debt	3.33B	2.82B	3.03B	3.01B	3.00B	3.51B
Total Liabilities	5.63B	5.16B	5.62B	5.78B	5.89B	6.16B
Stockholders Equity	1.61B	1.64B	1.77B	2.08B	2.16B	2.28B
Cash Flow
Free Cash Flow	437.97M	426.82M	256.20M	339.17M	-40.59M	354.33M
Operating Cash Flow	509.89M	511.35M	416.51M	715.79M	747.12M	985.77M
Investing Cash Flow	-111.70M	-235.93M	-36.49M	-1.09B	-532.66M	-875.22M
Financing Cash Flow	174.12M	-404.07M	-356.40M	-367.71M	-1.05B	801.72M

Jourdeness Group Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4190 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:3164	71Outperform	TWD 1.44B	23.26	―	4.78%	1.32%	80.16%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6846	55Neutral	TWD 1.33B	12.56	―	8.05%	-3.09%	-27.22%
TW:1805	44Neutral	TWD 1.31B	71.17	―	―	-59.33%	-94.38%
TW:6578	42Neutral	TWD 1.21B	-51.66	―	2.37%	21.50%	-5.51%
TW:4190	40Underperform	TWD 1.29B	-13.64	―	2.28%	-1.05%	34.07%
TW:6431	38Underperform	TWD 1.45B	-7.35	―	―	-14.57%	13.16%

* General Sector Average

Performance Comparison

TW:4190 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4190	Jourdeness Group Ltd.	21.95	-8.98	-29.04%
TW:1805	Better Life Group Co., Ltd.	9.70	-2.55	-20.82%
TW:3164	GenMont Biotech, Inc.	16.75	-0.96	-5.41%
TW:6431	Kuangli Bio-Tech Holdings Co., Ltd.	14.55	-1.70	-10.46%
TW:6578	Dabomb Protein Biotech Corporation	17.00	-2.65	-13.49%
TW:6846	Greenyn Biotechnology Co., Ltd.	49.00	-23.75	-32.65%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Jourdeness Group Ltd. AI Stock Analysis